# Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

> **NCT02582697** · PHASE3 · RECRUITING · sponsor: **University of Sydney** · enrollment: 500 (estimated)

## Conditions studied

- Germ Cell Tumor

## Interventions

- **DRUG:** Bleomycin (active name: Bleomycin Sulfate)
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Pegylated G-CSF (Pegfilgrastim)
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02582697
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-02
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582697, "Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02582697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*